

Article

Not peer-reviewed version

Faricimab Reverts VEGF-A₁₆₅-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells

Dominik M. Jung , [Isabell Fuezy](#) , [Lyubomyr Lytvynchuk](#) , [Heidrun L. Deissler](#) *

Posted Date: 13 March 2025

doi: 10.20944/preprints202503.0928.v1

Keywords: retinal endothelial cells; VEGF-A; angiopoietin-2; anti-VEGF drugs; faricimab; cell index measurement; tight junction; claudin-1; claudin-5; plasmalemma vesicle-associated protein



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Faricimab Reverts VEGF-A₁₆₅-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells

Dominik M. Jung ¹, Isabell Fuezy ¹, Lyubomyr Lytvynchuk ^{1,2,3} and Heidrun L. Deissler ^{1,*}

¹ Department of Ophthalmology, Justus Liebig University Giessen, Giessen, Germany

² Department of Ophthalmology, University Hospital Giessen and Marburg GmbH, Campus Giessen, Germany

³ Karl Landsteiner Institute for Retinal Research and Imaging, Vienna, Austria

* Correspondence: Heidrun.L.Deissler@augen.med.uni-giessen.de

Abstract: VEGF-A₁₆₅-induced persistent dysfunction of the barrier formed by immortalized bovine retinal endothelial cells (iBREC) is only transiently reverted by inhibition of VEGF-A-driven signaling. As angiopoietin-2 (Ang-2) enhances the detrimental action of VEGF-A₁₆₅, we studied if binding of both growth factors by the bi-specific antibody faricimab sustainably reverts barrier impairment. Confluent monolayers of iBREC were exposed to VEGF-A₁₆₅ for one day before 10-1000 µg/ml faricimab were added for additional five days. To assess barrier function, we performed continuous electric cell-substrate impedance, i.e. cell index, measurements. VEGF-A₁₆₅ significantly lowered the cell index values which recovered to normal values within hours after addition of faricimab. Stabilization lasted for two to five days depending on the antagonist's concentration. As determined by Western-blotting, only ≥100 µg/ml faricimab efficiently normalized altered expression of claudin-1 and claudin-5, but all concentrations prevented further increase of plasmalemma vesicle-associated protein induced by VEGF-A₁₆₅; these proteins are involved in barrier stability. Secretion of Ang-2 by iBREC was significantly higher after exposure to VEGF-A₁₆₅, and strongly reduced by faricimab even below basal levels; aflibercept was significantly less efficient. Taken together, faricimab sustainably reverts VEGF-A₁₆₅-induced barrier impairment, and protects against detrimental actions of Ang-2 by lowering its secretion.

Keywords: retinal endothelial cells; VEGF-A; angiopoietin-2; anti-VEGF drugs; faricimab; cell index measurement; tight junction; claudin-1; claudin-5; plasmalemma vesicle-associated protein

1. Introduction

Vascular endothelial growth factor-A (VEGF-A)₁₆₅ elevates the permeability of the endothelial cell (EC) layer of retinal microvessels eventually resulting in vision-threatening macular edema, a hallmark of burdening retinal diseases such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and myopic retinopathy [1–3]. In vitro, VEGF-A₁₆₅ induces barrier impairment of primary and immortalized retinal endothelial cells (REC) isolated from various species including human through activating VEGF receptor 2 (VEGFR2)-driven signaling [2,4–7].

The function of the barrier formed by microvascular EC, e.g. REC, can reliably be assessed by continuous electric cell-substrate impedance measurements with a microelectronic biosensor system for cell-based assays, i.e. determination of the so-called cell index (CI): A high CI reflects a tight barrier and vice versa [8–10]. A few hours after addition of VEGF-A₁₆₅ to a confluent monolayer of immortalized bovine REC (iBREC), the CI values start to decline and these low CI values last at least for several days [10–13]. A similar severe impairment of the barrier has also been observed for human REC (huREC) [14]. Interfering with VEGF-A-mediated signaling through binding of the growth factor by VEGF antagonists ranibizumab and brolicizumab efficiently, but only transiently, reverts VEGF-A₁₆₅-induced changes: Low cell index values are normalized within one day but start to decline

during extended incubation for up to five days [12,15,16]. Inhibition of VEGFR2 completely normalizes low CI values only when inhibitors were added one day after exposure to the growth factor but not on day three [5,13]. Therefore, modulation of VEGF-A₁₆₅'s action by other growth factors or cytokines is likely, and the angiogenic growth factor angiopoietin-2 (Ang-2) seems to be a promising candidate: Ang-2 is secreted by iBREC during prolonged exposure to VEGF-A₁₆₅ although at much lower concentrations compared to other microvascular EC [17–20]. Studies using a rabbit retina hyperpermeability model showed that concentrations of Ang-2 in the vitreous are also strongly elevated after intravitreal injection of VEGF-A₁₆₅, significantly prevented by the VEGF-binding proteins aflibercept, brolocizumab and ranibizumab [21,22]. Ang-2 stimulates proliferation of iBREC, but does not impair their very tight barrier [17]. The growth factor rather significantly enhances the detrimental action of VEGF-A₁₆₅, and this disturbance is efficiently prevented by blocking VEGF-A-mediated signal transduction [17]. On the cellular level, extended exposure of iBREC to VEGF-A₁₆₅ over several days changes expression of proteins regulating para- and transcellular flow, also observed for primary bovine and human REC: Amounts of tight junction (TJ)-protein claudin-1 are persistently reduced, those of TJ-protein claudin-5 remain stable early after addition of the growth factor but increase later on [2,5–7,10,12,13,17]. The key regulator of transcellular flow, plasmalemma vesicle-associated protein (PLVAP), is hardly expressed by unchallenged REC but its expression is dramatically enhanced after exposure to VEGF-A₁₆₅ [12,23–25]. VEGF-A antagonists brolocizumab and ranibizumab completely reverse VEGF-A₁₆₅-induced changes of claudin-1 and claudin-5, but only partly those of PLVAP [12].

Using our well-established model of immortalized microvascular EC of the bovine retina (iBREC) we now investigated if dual binding of both growth factors VEGF-A and Ang-2 by the bi-specific IgG faricimab efficiently and sustainably reverses VEGF-A₁₆₅-induced changes of the barrier formed by these cells, i.e. low cell index values as a measure of barrier function, and altered expression of claudin-1, claudin-5 and PLVAP [11,20]. In order to mimic patients' situation, we focused on extended treatment of the cells with the effectors for up to six days. Although of non-human origin, primary and immortalized microvascular EC of the bovine retina represent an authentic in vitro model of the highly impermeable barrier formed by REC in vivo: Their monolayers establish a very strong barrier reflected by persistently high values of the transendothelial electrical resistance or the CI, accompanied by strong expression of TJ-protein claudin-5 typical for microvascular EC, and very low if any expression of PLVAP [2,7,10,12,13,24,26]. The homogenous cell line iBREC can be stimulated by human growth factors, and, most importantly, is free of contaminating cells of other types often found in primary cultures which might affect the accuracy of in vitro studies [2,11,17].

2. Results

2.1. General Information

All experiments to investigate the changes induced by VEGF-A₁₆₅ and subsequent treatment with faricimab were performed at least thrice always with confluent monolayers of iBREC. To ensure maintenance of their typical phenotype, cells were cultured in cell culture medium adapted to their special needs [27]. After establishing a tight monolayer, recombinant human VEGF-A₁₆₅ (final concentration of 50 ng/ml) was added to the cells to induce a dysfunction of the barrier. One day later faricimab (final concentrations of 10 µg/ml, 100 µg/ml or 1 mg/ml) was placed in the cell culture medium, thus VEGF-A₁₆₅ was present until the end of the experiment [12,13]. In control experiments, cells were processed in exactly the same way without studied effector(s). Investigated concentrations of faricimab can easily be achieved by intravitreal injections [28].

2.2. Faricimab Strongly Suppressed Higher Secretion of Ang-2 by VEGF-A₁₆₅-Treated iBREC

Extended cultivation of cells over several days could lead to cellular stress, therefore, we determined if long-term cultured iBREC secreted interleukin (IL)-6, a marker of cellular stress [27,29].

However, the cytokine was not detected by ELISA in supernatants obtained from confluent iBREC monolayers cultured for up to nine days unaltered by exposure to 50 ng/ml VEGF-A₁₆₅; values were below the minimal detectable dose of 78 pg/ml. Therefore, chosen conditions of cultivation support establishment and maintenance of a monolayer of healthy microvascular endothelial cells.

Faricimab binds strongly to its target protein VEGF-A₁₆₅, and to confirm that this complex is still stable after extended treatment of VEGF-A₁₆₅-challenged iBREC with faricimab for five days, we determined amounts of non-complexed VEGF-A in supernatants and cell extracts. Faricimab and the detection antibody of the used ELISA likely bind to the same region of the growth factor, therefore only unbound VEGF-A can be measured [20]. A four-fold molar excess of faricimab over VEGF-A₁₆₅ indeed prevents detection of the growth factor by the used ELISA [30]. As anticipated, relevant amounts of the growth factor were measured in cell culture supernatants and cell extracts of iBREC exposed to the growth factor for six days (supernatants: 19 ± 6 ng/ml VEGF-A; N=24; cell extracts: 0.25 ± 0.11 ng/10⁶ cells VEGF-A; N=6). However, signals obtained from supernatants or extracts of cells additionally exposed to faricimab (final concentrations: 10 µg/ml, 100 µg/ml and 1 mg/ml) were below the minimal detectable dose of 9 pg/ml, and this did not depend on the antagonist's concentration.

In addition, Western blot analyses of cell extracts confirmed presence of internalized faricimab even after exposure to the growth factor and subsequently to the antagonist for as long as five days (Figure 1). However, significantly less faricimab was detected when cells had been treated with the lowest concentration of 10 µg/ml faricimab.

We also studied whether faricimab changed secretion of Ang-2 by VEGF-A-challenged iBREC. Faricimab does not interfere with binding of the detection antibody to Ang-2 of the used ELISA, i.e. free Ang-2 and Ang-2/faricimab complexes are detected [17]. Low concentrations of ~250 pg/ml Ang-2 were measured in the supernatant of unchallenged iBREC and levels were significantly higher three and six days after addition of VEGF-A₁₆₅ (Figure 2) [17]. Increased secretion of Ang-2 was efficiently lowered by subsequent exposure to the VEGF antagonist aflibercept (Figure 2). Most interestingly, faricimab reduced Ang-2 levels much more pronounced, even significantly below basal levels (Figure 2). Relevant differences between both time points were not observed.




Figure 1. Faricimab is taken up by VEGF-A₁₆₅-exposed iBREC. The VEGF antagonist was added to VEGF-A₁₆₅-exposed iBREC before cells were harvested five days later for preparation of cell extracts and subsequent Western-blotting. Specific signals were normalized to those obtained from cells treated with VEGF-A₁₆₅ and 1 mg/ml faricimab. Pooled data of several Western blot experiments were analyzed as described in section “4.6 Statistical analyses”, and are shown as scatter plots with means and standard deviations. **) p<0.01, (***) p<0.001; only statistically significant differences are marked. Original images are shown in supplementary Figure S3. Even after extended incubation, internalized VEGF antagonist can still be detected in a concentration dependent manner.




Figure 2. Faricimab sustainably counteracted higher secretion of Ang-2 by VEGF-A₁₆₅-exposed iBREC. Confluent monolayers of iBREC were treated with VEGF-A₁₆₅ for one day, and subsequently with aflibercept or faricimab for additional two or five days, before cell culture supernatants were collected for determination of Ang-2 by ELISA. Pooled Ang-2-specific signals were normalized, and analyzed as described in Materials and Methods. **) p<0.01, (***) p<0.001, ****) p<0.0001; indicating statistically significant differences only. Secretion of Ang-2 was significantly increased after treatment with VEGF-A₁₆₅ for three or six days, respectively. Aflibercept efficiently normalized Ang-2 levels, but faricimab lowered amounts of Ang-2 significantly more pronounced.

2.3. Faricimab Efficiently Reverted VEGF-A₁₆₅-Induced Barrier Impairment

To assess the capability of faricimab to efficiently and sustainably revert the VEGF-A₁₆₅-induced barrier impairment, we measured the cell index (CI) of an iBREC monolayer. After establishing a tight barrier as indicated by high CI values of ~20, the growth factor was added. One day later, the antagonist was placed in the cell culture medium and the CI was continuously monitored for up to six days (Figure 3).




Figure 3. VEGF-A₁₆₅-induced low CI values were efficiently normalized after subsequent exposure to faricimab. Confluent monolayers of iBREC were treated with 50 ng/ml VEGF-A₁₆₅ for one day before faricimab at final concentrations of (a, d) 10 µg/ml (n=7), (b, d) 100 µg/ml (n=8) or (c, d) 1 mg/ml (n=6) was added, and the CI was continuously determined. Control cells (n=6) were exposed to vehicle only. CI values were normalized in relation to those measured just before the addition of VEGF-A₁₆₅. (a)-(c) Graphs on the left show means only, those in the middle and on the right means ± standard deviations. VEGF-A₁₆₅ induced a significant and persistent decline of the CI values. (a) After addition of 10 µg/ml faricimab, low CI values increased to normal levels within hours, but they only remained similar to those of control cells for about two days. (b, c) Normal CI values were quickly re-established by 100 or 1000 µg/ml faricimab, and they did not significantly differ from those of control cells throughout extended exposure to faricimab. (d) 1000 µg/ml faricimab allowed for the most persistent stabilization; only means are shown.

The growth factor induced a persistent reduction of the CI values indicative of impairment of the cells' barrier (Figure 3). After addition of faricimab at a final concentration of 10 µg/ml to VEGF-A₁₆₅-pretreated iBREC, the CI values increased and reached normal values twelve hours later (Figure 3a). CI values remained similar to those obtained for control cells for about two days, before

they started to decline again. CI values were then significantly lower compared to those of the control cells but still significantly higher compared to those of VEGF-A₁₆₅-exposed iBREC (Figure 3a). At a concentration of 100 µg/ml, faricimab reverted VEGF-A₁₆₅-lowered CI values also within hours; CI values remained close to those of the control cells even late after the antagonist's addition (Figure 3b). Increasing the concentration of faricimab to 1 mg/ml also resulted in rapid reversion of VEGF-A₁₆₅-reduced CI values, and normalized CI values did not differ from those of control cells even during extended incubation for five days (Figure 3c). Accordingly, faricimab at a concentration of 1 mg/ml was significantly more efficient compared to 10 µg/ml or 100 µg/ml, respectively (Figure 3d).

2.4. Faricimab Reverted VEGF-A₁₆₅-Induced Changes of Expression of Claudin-1 and PLVAP

Constantly low amounts of the TJ-protein claudin-1 correlate with VEGF-A₁₆₅-induced barrier impairment whereas expression of TJ-protein claudin-5 is significantly higher only after extended exposure to the growth factor, and that of adherens junction (AJ) protein vascular endothelial cadherin (VEcadherin) remains largely unchanged [2,10,12,13,31]. To investigate if faricimab sustainably normalized VEGF-A₁₆₅-induced changes, we assessed expression of these candidate proteins (Figure 4).

As anticipated, low amounts of claudin-1 (Figure 4a, d) were observed after exposure to VEGF-A₁₆₅ for one, three or six days. When cells had been treated with VEGF-A₁₆₅ for one day and subsequently with faricimab for only two days, expression of claudin-1 was efficiently re-instated independent on the antagonist's concentration (Figure 4a). However, after extended treatment of VEGF-A₁₆₅-exposed iBREC with 10 µg/ml faricimab, expression of claudin-1 was significantly lower at this later time point (relative expression of claudin-1: 0.77 ± 0.27 on day 6 (N=9) compared to 1.47 ± 0.64 on day 3 (N=9); $p=0.014$) (Figure 4a, left panel). Although expression of claudin-1 was still significantly higher than that observed after exposure to VEGF-A₁₆₅ only, it was now significantly lower compared to that of control cells (Figure 4a, left panel). In contrast, during prolonged exposure of VEGF-A₁₆₅-challenged iBREC with ≥ 100 µg/ml faricimab, expression of claudin-1 remained stable, and was significantly higher compared to that of VEGF-A-exposed cells (Figure 4a, middle and right panels).

Only after treatment with VEGF-A₁₆₅ for six days, significantly more TJ-protein claudin-5 was expressed, but not when cells were also exposed to faricimab (Figure 4b, d). Extended exposure of VEGF-A₁₆₅-pretreated cells with 10 µg/ml faricimab reduced expression of claudin-5 (relative expression of claudin-5: 0.82 ± 0.21 on day 6 (N=10) compared to 1.41 ± 0.46 on day 3 (N=9); $p=0.004$); it was also significantly lower compared to that of control cells (Figure 4b, left panel). Expression of VEcadherin remained mostly stable; it was only significantly lower when VEGF-A₁₆₅-exposed cells had also been treated with 1 mg/ml faricimab for additional five days (Figure 4c, right panel).




Figure 4. Faricimab reverted VEGF-A₁₆₅-induced lower expression of TJ-protein claudin-1. iBREC were pre-treated with 50 ng/ml VEGF-A₁₆₅ for one day, before faricimab was added, and cells were harvested for preparation of cell extracts and subsequent Western-blotting at indicated time points. **(a)-(c)** Specific signals of Western blot analyses (N \geq 5 per condition and time point) were normalized as described in Materials and Methods. Pooled data are shown as graphs with means and standard deviations. VEGF-A compared to control: *) p<0.05, ****) p<0.0001; VEGF-A compared to VEGF-A + faricimab: *) p<0.05, **) p<0.01, ***) p<0.001; VEGF-A + faricimab compared to control: §) p<0.05; only statistically significant differences are marked. **(a)** VEGF-A-induced low expression of claudin-1 was efficiently normalized by \geq 100 μ g/ml faricimab two and five days after the antagonist's addition. Reversion of claudin-1 expression by 10 μ g/ml faricimab was only achieved early after its addition. **(b)** Claudin-5 amounts increased over time, lowered again by faricimab. **(c)** Only extended exposure to VEGF-A₁₆₅ followed by 1 mg/ml faricimab significantly lowered amounts of VEcadherin. **(d)** Typical images of Western blot analyses of which original images are shown in supplementary Figure S1-S3.

Expression of the regulator of intracellular transport PLVAP by iBREC is induced by VEGF-A₁₆₅; values of relative expression of PLVAP were: 0.34 ± 0.22 (N=4) for control compared to normalized signals of VEGF-A₁₆₅ of 1.00 (N=4), $p=0.009$. Even stronger signals were observed after treatment of the cells for three or six days, respectively. Interestingly, VEGF-A-induced higher PLVAP expression was efficiently counteracted by faricimab only after prolonged treatment regardless of its concentration (Figure 5).




Figure 5. Faricimab counteracted VEGF-A₁₆₅-induced high expression of PLVAP. Cell extracts of iBREC treated with VEGF-A₁₆₅ and subsequently with faricimab were analyzed by Western-blotting as described above. The specific signal is present at ~60 kDa, and faint bands at 70 kDa and ~100 kDa are unspecific [12]. Specific Western blot signals were normalized to those obtained from VEGF-A-exposed cells. Pooled data – analyzed as described in section “4.6 Statistical analyses” – are shown as scatter plot with means and standard deviations. *) $p<0.01$, ***) $p<0.001$, ****) $p<0.0001$; only statistically significant differences are indicated. Original images are shown in supplementary Figures S2 and S3. Only prolonged treatment with faricimab was sufficient to completely down-regulate the VEGF-A₁₆₅-induced expression of PLVAP.

Taken together, faricimab efficiently reverted VEGF-A₁₆₅-changed expression of proteins involved in regulation of barrier stability, although significant deviations from normal expression levels were observed especially late after addition of the growth factor and its antagonist.

3. Discussion

VEGF-A₁₆₅ persistently impairs the barrier formed by a monolayer of primary and immortalized microvascular retinal endothelial cells [2,5–7,10,12,13]. Since blocking of VEGF-A-driven signal transduction by complexing the growth factor with VEGF-binding proteins or by inhibiting the tyrosine kinase activities of the growth factor’s receptor only transiently revert VEGF-A₁₆₅-induced barrier impairment, we studied if additional binding of Ang-2 by faricimab is superior [12,13,20]. Albeit in contrast to previously published observations with commercially available HuREC, we have recently found, that Ang-2 alone does not change the barrier function of iBREC, but significantly enhances the detrimental changes induced by VEGF-A₁₆₅ [17,18]. However, iBREC represent a very reliable and more authentic model of the tight retinal-blood barrier, because similar to primary bovine REC this cell line establishes a very tight barrier [5,12,13,17,24]. In spite of the non-human nature of the used cell model, it is a reasonable assumption that humanized IgG faricimab which competes with binding of *human* Ang-2 to its receptor Tie2, also efficiently complexes *bovine* Ang-2 [20]. The overall identity and similarity of the human and bovine homologues of Ang-2 are extremely

high, and – most importantly – the amino acid sequences of the receptor binding regions of human and bovine Ang-2 are identical [32].

Aflibercept normalized extracellular Ang-2 elevated by VEGF-A₁₆₅ treatment of iBREC, and our finding is in accordance with previously published observations using a rabbit retina hyperpermeability model [22]. Dual binding of both growth factors by faricimab was even more potent, suggesting that besides VEGF-driven signaling, the Tie2 pathway is also involved in down-regulating of secretion of Ang-2 [33]. The growth factor likely acts through an internal autocrine mechanism, in iBREC obviously efficiently counteracted by the internalized antagonist [34]. In this context it is of interest that intravitreal injection of faricimab but not of aflibercept lowers the concentration of unbound Ang-2 in aqueous humor of patients with diabetic macular edema [35].

Modulation of VEGF-A₁₆₅ detrimental changes of the barrier are observed only with Ang-2 concentrations which are an order of magnitude higher compared to those secreted by iBREC [17]. Nevertheless, one might speculate that dual binding of both growth factors is superior to reinstate and, even more importantly, maintain a functional barrier that had been compromised by pre-treatment with VEGF-A₁₆₅. Indeed, high concentrations of faricimab ($\geq 100 \mu\text{g/ml}$) efficiently reverted changes induced by the growth factor including normalization of cell index values, and expression of proteins involved in barrier stabilization, e.g. claudin-1 and claudin-5 [2,5,6]. In accordance with our previous findings, expression of the AJ-protein VEcadherin remained largely unchanged by the effectors, although its amounts were significantly lower after exposure of the cells to VEGF-A₁₆₅ followed by the high dose of the pharmacological formulation of faricimab, i.e. Vabysmo [12,13]. It is a reasonable assumption that the surfactant polysorbate-20 – a component of the formulation – is responsible for the observed altered expression of VEcadherin: Expression of VEcadherin is significantly reduced by $\geq 0.0002\%$ polysorbate-20 [36]. Surfactants prevent destabilization and precipitation of proteins, but they can be subject to modification and degradation by cellular enzymes [37]. However, low amounts of VEcadherin obviously do not necessarily correlate with a dysfunctional barrier, because the CI values are still high [36]. Similar to our observations with VEGF-A-binding proteins ranibizumab or brolocizumab, the lowest faricimab concentration of $10 \mu\text{g/ml}$ only transiently reinstated low CI values [12,13]. Subtle but significant deviations from the normal expression patterns of TJ-proteins claudin-1 and claudin-5 might account for the observed barrier impairment, because their reduced expression correlates with a dysfunctional barrier [2,10,27]. Whether or not these subtle changes result from residual VEGF-A-driven signaling is an interesting speculation: Relevant amounts of unbound intra- or extracellular VEGF-A were not detected even late after the antagonist's addition suggesting that the growth factor is very likely completely bound by faricimab present in an excess. However, complexing the growth factor by cellular proteins, e.g. (soluble) VEGF receptors, cannot be ruled out, and according to the manufacturer's instructions, these complexes would not be measured by the used ELISA. Even low amounts of VEGF-A bound to the VEGF receptors – either at the cell surface or intracellular – could initiate or maintain VEGF signaling, eventually leading to barrier impairment [4,38].

Low expression of the regulator of transcellular flow PLVAP is a key feature of microvascular cells establishing a tight barrier, and its increased expression is associated with higher permeability of the endothelial layer [24,25]. De novo-synthesis of PLVAP is induced by VEGF-A₁₆₅, and PLVAP protein can be detected at the earliest after one to two days [12,23,24,39,40]. Faricimab prevented further VEGF-A₁₆₅-induced increase of PLVAP, but – likely due to a slow turn-over of the protein – this was achieved only late after the antagonist's addition. PLVAP was still strongly expressed by VEGF-A₁₆₅-challenged cells exposed to faricimab for only two days despite a closed barrier as indicated by high cell index values. Therefore, proper function of the iBREC barrier appears to be predominantly determined by the balanced expression of TJ-proteins, i.e. claudin-1 and claudin-5, and consequently by restricted paracellular flow. Dual inhibition of VEGF-A and Ang-2 counteracts VEGF-A₁₆₅-induced PLVAP expression to a greater extent than blocking VEGF-A alone with ranibizumab as previously shown, suggesting a direct or indirect role of Ang-2 in regulation of PLVAP expression [12,40].

Taken together, faricimab efficiently reverts the VEGF- A_{165} -induced dysfunction of the barrier formed by an iBREC monolayer, and this stabilization can be maintained for several days with high concentrations of the antagonist. Of course, conclusions drawn from in vitro experimentation based on models with certain limitations cannot be transferred directly to the clinical assessment of patients and their used therapy, but, nevertheless, our findings may at least partially translate to the in vivo situation of (diabetic) macular edema caused by increased permeability of the retinal capillary endothelial cell monolayer due to VEGF- A_{165} present in the vitreous humor [3,42]. Pathogenesis of diabetic macular edema is also accompanied by elevated concentrations of Ang-2 in the vitreous humor, and as mentioned above, the growth factor strengthens the detrimental effects of VEGF- A_{165} in vitro [17,20,42–44]. Accordingly, clinical studies showed substantially maintained improvement of visual acuity and central subfield thickness by intravitreal injections of faricimab [28]. That faricimab strongly down-regulates secretion of Ang-2 in vitro as well as in vivo, suggests an additional protective role of the antagonist in early and late stages of diabetic retinopathy, e.g. by counteracting Ang-2-caused loss of retinal pericytes or Ang-2-stimulated retinal neovascularization [35,45].

4. Materials and Methods

4.1. Antibodies and Reagents

Information on antibodies used in this study is summarized in Table 1. The bi-specific antibody faricimab (Vabysmo; 120 mg/ml in 3.1 mg/ml L-histidine, 1.044 mg/ml L-methionine, 1.46 mg/ml NaCl, 54.8 mg/ml D-sucrose, 0.04% polysorbate-20, pH 5.5) and the Fc fusion protein aflibercept (Eylea; 40 mg/ml aflibercept in 10 mM sodiumphosphate, 40 mM NaCl, 0.03% polysorbate-20, 5% sucrose, pH 6.2) were purchased from Roche Pharma AG (Grenzach-Wyhlen, Germany) or Bayer AG (Berlin, Germany), respectively [20,21]. Recombinant human *Sf21*-expressed VEGF- A_{165} (#293VE) was bought from bio-techne (Wiesbaden, Germany), dissolved and stored as described [17].

Table 1. Primary and secondary antibodies.

Target	Host, Type and Conjugate	Source ^{a)}	Working concentration
actin	mouse, monoclonal	clone 5J11, Novus Biologicals, #NBP2-25142	700 ng/ml
β -actin	mouse, monoclonal	clone BA3R, Invitrogen, #MA5-15739	100 ng/ml
claudin-1	rabbit, polyclonal	Invitrogen, #51-9000	250 ng/ml
claudin-5	rabbit, polyclonal	Invitrogen, #34-1600	100 ng/ml
PLVAP ^{b)}	rabbit, polyclonal	Invitrogen, #PA5-110183	2 μ g/ml
VEcadherin	rabbit, polyclonal	Cell Signaling Technology B.V., #2158	1:2000
whole rabbit IgG	goat, polyclonal, coupled to HRP	Biorad, #170-5046	1:15000
whole mouse IgG	goat, polyclonal, coupled to HRP	Biorad, #170-5047	1:30000

^{a)} Biorad, Munich, Germany; Cell Signaling Technology B.V., Frankfurt, Germany; Invitrogen via Thermo Fisher Scientific, Schwerte, Germany; Novus Biologicals via bio-techne, Wiesbaden, Germany. ^{b)} HRP, horseradish peroxidase; PLVAP, plasmalemma vesical-associated protein; VEcadherin, vascular endothelial cadherin.

4.2. Cultivation of iBREC

Telomerase-immortalized microvascular endothelial cells from bovine retina (iBREC) – established in our laboratory – were cultivated on surfaces coated with fibronectin (Corning, Amsterdam, The Netherlands) in Endothelial Cell Growth Medium MV (ECGM; #C-22120, Promocell, Heidelberg, Germany) containing 1 g/l glucose, 0.4% Endothelial Cell Growth

Supplement/H, 90 µg/ml heparin, 10 ng/ml human epidermal growth factor (hEGF), 100 nM hydrocortisone, 5% fetal bovine serum (FBS; all supplements were from Promocell) and 300 µg/ml geneticin (Thermo Fisher Scientific, Schwerte, Germany) as described in great detail elsewhere [2,5,10–13]. Characterization of iBREC which were used from passages 25 to 50 counting from the stage of primary culture, and their responses to stimulation with human growth factors have been described in great detail [2,10–13].

4.3. Cell Index Measurements

The cell index (CI) was determined to assess the stability of the barrier formed by a monolayer of iBREC by electric cell-substrate impedance measurements using the microelectronic biosensor system for cell-based assays xCELLigence RTCA DP (Agilent, OLS, Bremen, Germany) as previously described [5,10]. Briefly, cells were cultured in ECGM-1 (same as ECGM lacking hEGF, but containing 1 µg/ml fibronectin) until a confluent cell monolayer was reached, indicated by a constantly high cell index (CI ~ 20) about four days later. Then, the cell culture medium was replaced by ECGM-1, and after one day VEGF-A₁₆₅ (final concentration of: 50 ng/ml) was added and cells were incubated for another 24 hours. Faricimab (final concentration of: 10 µg/ml, 100 µg/ml or 1 mg/ml) was placed in the cell culture medium, and the CI was measured regularly every five minutes until the end of the experiments three or six days later. Recorded CI values were normalized in relation to those measured immediately before addition of VEGF-A₁₆₅ (RTCA Software Pro, Version 2.6.1, Agilent), and the results were converted to graphs showing means and standard deviations with GraphPad Prism 9.4.1 (GraphPad Software, Boston, USA) [10,12,17]. At the end of each experiment, integrity of the confluent monolayer was confirmed by microscopy, cell culture supernatants were collected and cells were harvested for preparation of cell extracts [17]. iBREC were also cultured in fibronectin-coated T25-cell culture flasks (Sarstedt, Nuembrecht, Germany), treated a similar manner as described above for harvesting cell culture supernatants and cells [17]. Samples were stored at -80°C for further analyses.

4.4. Measurement of VEGF-A₁₆₅, Ang-2 and IL-6 by ELISA

Confluent iBREC were pre-treated with 50 ng/ml VEGF-A₁₆₅ for one day before either faricimab or aflibercept (final concentrations: 10 µg/ml or 100 µg/ml) were added, and cell culture supernatants were harvested two and five days after addition of the inhibitors. Possibly secreted Ang-2 was determined in undiluted cell culture supernatants using Angiopoietin-2 Quantikine ELISA Kit (#DNAG20, bio-technie). To determine non-complexed VEGF-A in cell culture supernatants or cell extracts of iBREC exposed to 50 ng/ml VEGF-A₁₆₅ and subsequently to faricimab (final concentrations: 10 µg/ml, 100 µg/ml and 1 mg/ml) for five days, we used the Quantikine ELISA VEGF-A Immunoassay Kit (#DVE00, bio-technie). Supernatants of cells treated only with VEGF-A₁₆₅ and cell extracts were diluted 1:100 in phosphate buffered saline without Ca²⁺ and Mg²⁺ (Thermo Fisher Scientific), all other supernatants were not diluted (Deissler et al., 2022a). The marker of cellular stress IL-6 was measured with the IL-6 bovine uncoated ELISA Kit (#ESS0029, ThermoFisher Scientific) in undiluted cell culture supernatants of iBREC cultured in ECGM-1 with or without 50 ng/ml VEGF-A₁₆₅ for up to nine days [27,29]. Samples were processed at least in duplicates according to the manufacturers' instructions, and analyte-dependent absorbance was measured at 450 nm (reference wavelength: 570 nm) 15-20 minutes after addition of the stop solution as described previously [12,17,27]. Standard curves for Ang-2 (0 to 3000 pg/ml; minimal detectable dose: 8 pg/ml), VEGF-A (0 to 1250 pg/ml; minimal detectable dose: 9 pg/ml) or IL-6 (0 to 5000 pg/ml; minimal detectable dose: ≤78 pg/ml) were always generated in parallel to the analyses of samples. Ang-2-specific signals were normalized to those obtained from control cells, and results are presented as scatter plots also showing means ± standard deviations.

4.5. Western Blot Analyses of Protein Extracts

Proteins of relevance were analyzed by Western blot as previously described [17]. Chemiluminescence signals were scanned with the imaging system Fusion FX6 Edge V0.7 (Vilber Lourmat, Eberhadzell, Germany). To quantify the signals, peak volumes of the protein-specific bands (\geq five replicates) determined with EvolutionCapt Edge software (Version 18.12; Vilber Lourmat) were first standardized in relation to those of β -actin in the very same sample, and signals were normalized to those obtained from similarly processed control cells [12,17]. Because PLVAP is expressed only at very low levels by unchallenged iBREC, specific signals were normalized to those obtained from cells exposed to VEGF-A₁₆₅. For detection of faricimab we used polyclonal goat antibodies directed against the γ -chain of an human IgG (Invitrogen, #62-8420; 1:1000), and specific signals were set in relation to those obtained from cells exposed to VEGF-A₁₆₅ and 1 mg/ml faricimab [17]. Data from multiple Western blot experiments performed with several independently prepared cell extracts were pooled and presented as graphs, or as scatter plots always containing means and standard deviations.

4.6. Statistical Analyses

The One-sample t-test which takes the variation of the standard deviation into account although it appears to be zero, was used to compare antigen-specific Western blot signals from effector-treated cells to the hypothetical value of 1.00 of normalized signals. To compare several groups of antigen-specific Western blot or ELISA signals from differently treated cells, the one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test was used. Data obtained by CI measurements were analyzed with two-way ANOVA followed by Šidak's multiple comparison test. Differences resulting in p-values below 0.05 were considered significant. All statistical analyses were performed with GraphPad Prism 9.4.1; means and standard deviations are provided as numbers, graphs or in scatter plots

5. Conclusions

Dual binding of VEGF-A and Ang-2 by the bi-specific antibody faricimab lowered secretion of Ang-2, and most importantly reverted VEGF-A₁₆₅-induced barrier impairment. Low cell index values and altered expression of proteins regulating para- and transcellular flow were normalized although stabilization was only maintained with high concentrations of faricimab. The clinical significance of these findings for patients with macular edema lies in the ability of faricimab not only to counteract direct consequences of VEGF-A₁₆₅ but also to protect against the detrimental effects of Ang-2.

Supplementary Materials: The following supporting information can be downloaded at website of this paper posted on Preprints.org, Figures S1-S3: Original images of Western blot data shown in Figures 1, 4 and 5.

Author Contributions: Conceptualization, H.L.D. ; methodology, H.L.D.; validation, H.L.D; formal analysis, D.M.J., I.F. and H.L.D.; investigation, D.M.J. and I.F.; resources, L.L.; writing—original draft preparation, H.L.D.; writing—review and editing, H.L.D., I.F., D.M.J. and L.L.; visualization, H.L.D.; supervision, H.L.D. and L.L.; funding acquisition, H.L.D. All authors have read and agreed to the published version of the manuscript.

Funding: For this research, Heidrun L. Deissler received funding (investigator-initiated trial) from Roche Pharma AG, Grenzach-Wyhlen, Germany.

Institutional Review Board Statement and Informed Consent Statement: Not Applicable. No ethical conflicts have to be disclosed by the authors. This article does not contain any results of studies with human participants or animals.

Data Availability Statement: The original data used to support the findings of this study are either included in the article or are available from the corresponding author upon request.

Acknowledgments: The authors thank Stefanie Woelfel for technical assistance.

Conflicts of Interest: Lyubomyr Lytvynchuk is a consultant for Roche Pharma AG. Heidrun L. Deissler is receiving research funding from Roche Pharma AG, i.e. investigator-initiated trial. Dominik M. Jung, and Isabell Fuezy have no conflicts of interest to declare. The funder had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:

AJ	adherens junction
Ang-2	angiopoietin-2
CI	cell index
EC	endothelial cells
ECCGM	endothelial cell growth medium
FBS	fetal bovine serum
hEGF	human epidermal growth factor
HRP	horseradish peroxidase
HuREC	human retinal endothelial cells
(i)BREC	(immortalized) bovine retinal endothelial cells
PLVAP	plasma lemma vesicle associated protein
REC	retinal endothelial cells
TJ	tight junction
VEcadherin	vascular endothelial cadherin
VEGF-A	vascular endothelial growth factor-A
VEGFR	vascular endothelial growth factor receptor
WB	Western blot analyses

References

1. Antonetti, D.A.; Barber, A.J.; Hollinger, L.A.; Wolpert, E.B.; Gardner, T.W. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens 1. *J Biol Chem* **1999**, *274*, 23463-23467. <https://doi.org/10.1074/jbc.274.33.23463>.
2. Deissler, H.; Deissler, H.; Lang, G.E. Inhibition of VEGF is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. *Br J Ophthalmol* **2011**, *95*, 1151-1156. <https://doi.org/10.1136/bjo.2010.192229>.
3. Qaum, T.; Xu, Q.; Joussen, A.M.; Clemens, M.W.; Qin, W.; Miyamoto, K.; Hassessian, H.; Wiegand, S.J.; Rudge, J.; Yancopoulos, G.D.; Adamis, A.P. VEGF-initiated blood-retinal barrier breakdown in early diabetes. *Invest Ophthalmol Vis Sci* **2001**, *42*, 2408-2413.
4. Eichmann, A.; Simons, M. VEGF signaling inside vascular endothelial cells and beyond. *Curr Opin Cell Biol* **2012**, *24*, 188-193. <https://doi.org/10.1016/j.ceb.2012.02.002>.
5. Deissler, H.L.; Stutzer, J.-N.; Lang, G.K.; Grisanti, S.; Lang, G.E.; Ranjbar M. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A₁₆₅-induced disturbances of barriers formed by retinal endothelial cells or long-term cultivated ARPE-19 cells. *Exp Eye Res* **2020**, *194*, 108004. <https://doi.org/10.1016/j.exer.2020.108004>.
6. Suarez, S.; McCollum, G.W.; Bretz, C.A.; Yang, R.; Capozzi, M.E.; Penn, J.S. Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor- β/δ . *Invest Ophthalmol Vis Sci* **2014**, *55*, 8232-8240. <https://doi.org/10.1167/iovs.14-14217>.
7. Wisniewska-Kruk, J.; Hoeben, K.A.; Vogels, I.M.; Gaillard, P.J.; Van Noorden, C.J.; Schlingemann, R.O.; Klaassen, I. A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes. *Exp Eye Res* **2012**, *96*, 181-190. <https://doi.org/10.1016/j.exer.2011.12.003>.
8. Sun, M.; Fu, H.; Cheng, H.; Cao, Q.; Zhao, Y.; Mou, X.; Zhang, X.; Liu, X.; Ke, Y. A dynamic real-time method for monitoring epithelial barrier function in vitro. *Anal Biochem* **2012**, *425*, 96-103. <https://doi.org/10.1016/j.ab.2012.03.010>

9. Bischoff, I.; Hornburger, M.C.; Mayer, B.A.; Beyerle, A.; Wegener, J.; Fürst, R. Pitfalls in assessing microvascular endothelial barrier function: impedance-based devices versus the classic macromolecular tracer assay. *Sci Rep* **2016**, *6*, 23671. <https://doi.org/10.1038/srep23671>
10. Deissler, H.L.; Lang, G.K.; Lang, G.E. Inhibition of single routes of intracellular signaling is not sufficient to neutralize the biphasic disturbance of a retinal endothelial cell barrier induced by VEGF-A₁₆₅. *Cell Physiol Biochem* **2017**, *42*, 1493-1513. <https://doi.org/10.1159/000479213>.
11. Deissler, H.; Deissler, H.; Lang, G.K.; Lang, G.E. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. *Int J. Mol. Med* **2005**, *15*, 65-70. <https://doi.org/10.3892/ijmm.16.1.65>.
12. Deissler, H.L.; Rehak, M.; Busch, C.; Wolf, A. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells. *Exp Eye Res* **2022**, *216*, 108945. <https://doi.org/10.1016/j.exer.2022.108945>
13. Deissler, H.L.; Rehak, M.; Wolf, A. Impairment of the retinal endothelial cell barrier induced by long-term treatment with VEGF-A₁₆₅ no longer depends on the growth factor's presence. *Biomolecules* **2022**, *12*, 734. <https://doi.org/10.3390/biom12050734>.
14. McCann, M.; Li, Y.; Baccouche, B.; Kazlauskas, A. VEGF induces expression of genes that either promote or limit relaxation of the retinal endothelial barrier. *Int J Mol Sci* **2023**, *24*, 6402. <https://doi.org/10.3390/ijms24076402>
15. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina* **2006**, *26*, 859-870. <https://doi.org/10.1097/01.iae.0000242842.14624.e7>
16. Gaudreault, J.; Gunde, T.; Floyd, H.S.; Ellis, J.; Tietz, J.; Binggeli, D.; Keller, B.; Schmidt, A.; Escher, A. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. *Invest Ophthalmol Vis Sci* **2012**, *53*, 3025. ARVO Annual Meeting Abstract, Fort Lauderdale, USA, March 2012
17. Deissler, H.L.; Rehak, M.; Lytvynchuk, L. VEGF-A_{165a} and angiopoietin-2 differently affect the barrier formed by retinal endothelial cells. *Exp Eye Res* **2024**, *247*, 110062. <https://doi.org/10.1016/j.exer.2024.110062>.
18. Rangasamy, S.; Srinivasan, R.; Maestas, J.; McGuire, P.G.; Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. *Invest Ophthalmol Vis Sci* **2011**, *52*, 3784-3791. <https://doi.org/10.1167/iovs.10-6386>.
19. Eyre, J.J.; Williams, R.L.; Levis, H.J. A human retinal microvascular endothelial-pericyte co-culture model to study diabetic retinopathy in vitro. *Exp Eye Res* **2020**, *201*, 108293. <https://doi.org/10.1016/j.exer.2020.108293>.
20. Regula, J.T.; Lundh von Leithner, P.; Foxton, R.; Barathi, V.A.; Cheung, C.M.; Bo Tun, S.B.; Wey, Y.S.; Iwata, D.; Dostalek, M.; Moelleken, J.; Stubenrauch, K.G.; Nogoceke, E.; Widmer, G.; Strassburger, P.; Koss, M.J.; Klein, C.; Shima, D.T.; Hartmann, G. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. *EMBO Mol Med* **2016**, *8*, 1265-1288. <https://doi.org/10.15252/emmm.201505889>. Corrections in: *EMBO Mol Med* **2017**, *9*, 985. <https://doi.org/10.15252/emmm.201707895>. *EMBO Mol Med* **2019**, *11*, e10666. <https://doi.org/10.15252/emmm.201910666>
21. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J.P.; Daly, T.; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap: A VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci USA* **2002**, *99*, 11393-11398. <https://doi.org/10.1073/pnas.172398299>.
22. Lange C.; Tetzner, R.; Strunz, T.; Rittenhouse, K.D. Aflibercept suppression of angiopoietin-2 in a rabbit retinal vascular hyperpermeability model. *Transl Vis Sci Technol* **2023**, *12*, 5. <https://doi.org/10.1167/tvst.12.10.5>.
23. Bosma, E.K.; van Noorden, C.J.F.; Schlingemann, R.O.; Klaassen, I. The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. *Fluids Barriers CNS* **2018**, *15*, 24. <https://doi.org/10.1186/s12987-018-0109-2>

24. Bosma, E.K.; Darwesh, S.; Habani, Y.I.; Cammeraat, M.; Serrano Martinez, P.; van Breest Smalenburg, M.E.; Zheng, J.Y.; Vogels, I.M.C.; van Noorden, C.J.F.; Schlingemann, R.O.; Klaassen, I. Differential roles of eNOS in late effects of VEGF-A on hyperpermeability in different types of endothelial cells. *Sci Rep* **2023**, *13*, 21436. <https://doi.org/10.1038/s41598-023-46893-4>.
25. Wisniewska-Kruk, J.; van der Wijk, A.E.; van Veen, H.A.; Gorgels, T.G.; Vogels, I.M.; Versteeg, D.; Van Noorden, C.J.; Schlingemann, R.O.; Klaassen, I. Plasmalemma vesicle-associated protein has a key role in blood-retinal barrier loss. *Am J Pathol* **2016**, *186*, 1044-1054. <https://doi.org/10.1016/j.ajpath.2015.11.019>.
26. Kluger, M.S.; Clark, P.R.; Tellides, G.; Gerke, V.; Pober, J.S. Claudin-5 controls intercellular barriers of human dermal microvascular but not human umbilical vein endothelial cells. *Arterioscler Thromb Vasc Biol* **2014**, *33*, 489-500. <https://doi.org/10.1161/ATVBAHA.112.300893>
27. Busch, C.; Rehak, M.; Hollborn, M.; Wiedemann, P.; Lang, G.K.; Lang, G.E.; Wolf, A.; Deissler H.L. Type of culture medium determines properties of cultivated retinal endothelial cells: induction of substantial phenotypic conversion by standard DMEM. *Heliyon* **2021**, *7*, e06037. <https://doi.org/10.1016/j.heliyon.2021.e06037>
28. Wong, T.Y.; Haskova, Z.; Asik, K.; Baupal, C.R.; Csaky, K.G.; Eter, N.; Ives, J.A.; Jaffe, G.J.; Korobelnik, J.F.; Lin, H.; Murata, T.; Ruamviboonsuk, P.; Schlottmann, P.G.; Seres, A.I.; Silverman, D.; Sun, X.; Tang, Y.; Wells, J.A.; Yoon, Y.H.; Wykoff, C.C. YOSEMITE and RHINE investigators. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials. *Ophthalmology* **2024**, *131*, 708-723. <https://doi.org/10.1016/j.ophtha.2023.12.026>.
29. Strohl, L.L.; Zang, J.B.; Ding, W.; Manni, M.; Zhou, X.K.; Granstein, R.D. Norepinephrine and adenosine-5'-triphosphate synergize in inducing IL-6 production by human dermal microvascular endothelial cells. *Cytokine* **2013**, *64*, 605-612. <https://doi.org/10.1016/j.cyto.2013.08.00>
30. Lytvynchuk, L.; Nolte, K.L.; Deissler, H.L. Novel needle for intravitreal injections maintains activity of VEGF-binding proteins. ARVO Annual Meeting Abstract, Salt Lake City, USA, 6 May 2025.
31. Dejana, E.; Tournier-Lasserre, E.; Weinstein, B.M.. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. *Dev Cell* **2009**, *16*, 209-221. <https://doi.org/10.1016/j.devcel.2009.01.004>
32. Barton, W.A.; Tzvetkova-Robev, D.; Miranda, E.P.; Kolev, M.V.; Rajashankar, K.R.; Himanen, J.P.; Nikolov, D.B. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. *Nat Struct Mol Biol* **2006**, *13*, 524-532. <https://doi.org/10.1038/nsmb1101>
33. Maisonpierre, P.C.; Suri, C.; Jones, P.F.; Bartunkova, S.; Wiegand, S.J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T.H.; Papadopoulos, N.; Daly, T.J.; Davis, S.; Sato, T.N.; Yancopoulos, G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* **1997**, *277*, 55-60. <https://doi.org/10.1126/science.277.5322.55>.
34. Scharpfenecker, M.; Fiedler, U.; Reiss, Y.; Augustin, H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. *J Cell Sci* **2005**, *118*, 771-80. <https://doi.org/10.1242/jcs.01653>.
35. Diack, C.; Avery, R.L.; Cheung, C.M.G.; Csaky, K.G.; Gibiansky, L.; Jaminion, F.; Gibiansky, E.; Sickert, D.; Stoilov, I.; Cosson, V.; Bogman, K. Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema. *Transl Vis Sci Technol.* **2024**, *13*, 13. <https://doi.org/10.1167/tvst.13.11.13>.
36. Deissler, H.L.; Busch, C.; Wolf, A.; Rehak, M. Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro. *Sci Rep.* **2022**, *12*, 12493. <https://doi.org/10.1038/s41598-022-16770-7>.
37. Martos, A.; Koch, W.; Jiskoot, W.; Wuchner, K.; Winter, G.; Friess, W.; Hawe, A. Trends on analytical characterization of polysorbates and their degradation products in biopharmaceutical formulations. *J Pharm Sci* **2017**, *106*, 1722-1735. <https://doi.org/10.1016/j.xphs.2017.03.001>.
38. Bruns, A.F.; Shane, P.H.; Odell, A.F.; Jopling, H.M.; Hooper, N.M.; Zachary, I.C.; Walker, J.H.; Ponnambalam S. Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. *Traffic* **2010**, *11*, 161-174. <https://doi.org/10.1111/j.1600-854.2009.01001.x>

39. Guo, L.; Zhang, H.; Hou, Y.; Wie, T.; Liu, J. Plasmalemma vesicle-associated protein: A crucial component of vascular homeostasis. *Exp Ther Med* **2016**, *12*, 1639-1644. <https://doi.org/10.3892/etm.2016.3557>.
40. Hamilton, B.J.; Tse, D.; Stan, R.V. Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner. *J Cell Mol Med* **2019**, *23*, 920-933. <https://doi.org/10.1111/jcmm.13993>.
41. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E.; Nguyen, H.V.; Aiello, L.M.; Ferrara, N.; King, G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* **1994**, *331*, 1480-1487. <https://doi.org/10.1056/NEJM199412013312203>.
42. Peters, S.; Cree, I.A.; Alexander, R.; Turowski, P.; Ockrim, Z.; Patel, J.; Boyd, S.R.; Jousen, A.M.; Ziemssen, F.; Hykin, P.G.; Moss, S.E. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. *Cytokine* **2007**, *40*, 144-150. <https://doi.org/10.1016/j.cyto.2007.09.001>.
43. Watanabe, D.; Suzuma, K.; Suzuma, I.; Ohashi, H.; Ojima, T.; Kurimoto, M.; Murakami, T.; Kimura, T.; Takagi, H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. *Am J Ophthalmol* **2005**, *139*, 476-481. <https://doi.org/10.1016/j.ajo.2004.10.004>.
44. Klaassen, I.; Avery, P.; Schlingemann, R.O.; Steel, D.H.W. Vitreous protein networks around ANG2 and VEGF in proliferative diabetic retinopathy and the different effects of aflibercept versus bevacizumab pre-treatment. *Sci Rep* **2022**, *12*, 21062. <https://doi.org/10.1038/s41598-022-25216-z>
45. Hammes, H.P.; Lin, J.; Wagner, P.; Feng, Y.; Vom Hagen, F.; Krzizok, T.; Renner, O.; Breier, G.; Brownlee, M.; Deutsch, U. Angiopoietin-2 causes pericyte dropout in the normal retina: Evidence for involvement in diabetic retinopathy. *Diabetes* **2004**, *53*, 1104-1110. <https://doi.org/10.2337/diabetes.53.4.1104>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.